pharmaceuticals

• 

  Is France’s Economy a Surprise Threat to Eurozone?

  By Marlene Y. Satter, AdvisorOne  |  May 23, 2013

  The “bad boys” of the southern Eurozone, Greece, Spain and Italy, have gotten most of the attention when it comes to a possible Eurozone breakup, but the real threat may lie in an unexpected direction.

• 

  8 Most & Least Bullish Big Cities

  By Michael S. Fischer  |  April 22, 2013

  Investors around the country see the economic picture looking brighter. But how much brighter depends, in part, on where they live.

• Optimal Opportunities

  By Ed McCarthy, CFP  |  February 22, 2013

  While Actavis (ACT) narrowed its 2013 guidance expectations in the wake of an unexpected Concerta approval, the company is still poised to post close to 30% EPS growth and potentially double-digit annual EPS growth through 2016.

• 

  T. Rowe’s In-House Doctor Gives Healthcare Stock Picks for 2013

  By Joyce Hanson, AdvisorOne  |  November 28, 2012

  T. Rowe Price’s doctor is in–and diagnosing where the best stock picks can be found in the healthcare sector as reforms take hold next year.

• 

  Top 20 New Mega Donors

  By Michael S. Fischer  |  October 8, 2012

  Wealth-X tags the new crop of elite philanthropists following in the footsteps of Carnegie and Rockefeller.

• EEI: ‘Congress & President Must Act Now To Extend Current Dividend Tax Rates’

  September 25, 2012

  Today our nation is facing a series of tax hikes and mandatory spending cuts that threaten to send the economy over a ‘fiscal cliff’ at the end of the year.

• Core Competency

  August 23, 2012

  Solid growth and promising research and development pipelines bode well for companies that sell pharmaceutical and related health-care products.

• 

  What Obama Health Law Means Now That It’s Called a Tax

  By Joyce Hanson, AdvisorOne  |  July 6, 2012

  Considering the Patient Protection and Affordable Care Act’s broad reach, one simple thing is true of the PPACA’s potential tax and investment consequences: it’s complicated.

• 

  Too Much Cash

  By Alexei Bayer  |  May 24, 2012

  If, as some analysts suggest, holding such huge cash reserves has become necessary for companies to protect themselves, then the economy has become unbalanced and dangerously volatile.

• 

  Sell in May and Go to Health Care: S&P Capital IQ

  By Marlene Y. Satter, AdvisorOne  |  May 10, 2012

  The investment chestnut “Sell in May and go away” was the basis for a webinar conducted by Sam Stovall of S&P Capital IQ.